Evaluation of Exparel Adductor Canal Field Block for Pain Control After ACL Reconstruction

• Status: Recruiting
• Trial end date: 2022-03-02
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective, randomized study for adult patients presenting to the Carilion Clinic Institute of Orthopedics and Neurosurgery. Patients undergoing isolated ACL reconstruction will be eligible for inclusion. All patients will receive an adductor canal block (either with bupivacaine or Exparel. Patients will be given a pain diary for self-report of pill counts, pain scores, block duration, and pain control satisfaction). Pill counts and pain scores will also be taken by a team member at two and six-week post-operative visits. Primary outcomes include opioid requirements and pain scores.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Carilion Clinic
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• 18-65 years old

• Presenting to Carilion Clinic Institute of Orthopedics and Neuroscience

• Receiving an isolated, first-time ACL reconstruction

• Operation to be performed at the Roanoke Ambulatory Surgery Center

Exclusion Criteria:

• Prior opioid use within 30 days of operation

• Under 18 or over 65 years old

• Use of opioids for chronic pain management

• Patients with multi-ligament injuries

• Patients who are receiving a revision of a previously reconstructed ACL

• Patients with an allergy to the study drug(s)

• Patients not medically eligible for surgery

• Women who are pregnant